Zydus gets regulatory nod to sell diabetes drug in Mexico

Drug firm Zydus on Friday said it has received approval from the Mexican regulatory authority to market Lipaglyn (Saroglitazar Magnesium) used for the treatment of dyslipidemia in patients with diabetes.

The company has been granted marketing approval from the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) to commercialise Lipaglyn in Mexico, Zydus said in a statement.

"Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from hypertriglyceridemia and diabetic dyslipidemia," Zydus Group Chairman Pankaj Patel said.

This approval of Saroglitazar in Mexico is a major milestone for the company, he added.

"Lipaglyn is used for treatment of dyslipidemia in patients with diabetes mellitus type 2 and hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins," Zydus said.

Lipaglyn, a prescription drug, was first launched in India during September 2013, Zydus said.

"Over the last several years, more than 500,000 patients have been treated with Lipaglyn in India...," it added.

Shares of Cadila Healthcare, the listed entity of Zydus Group were today trading at Rs 467.50 per scrip on BSE, down 2.33 per cent from its previous close.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel